JP2018516931A - 末梢動脈疾患を処置するためのｉｌ−１ベータ結合抗体の使用 - Google Patents

末梢動脈疾患を処置するためのｉｌ−１ベータ結合抗体の使用 Download PDF

Info

Publication number
JP2018516931A
JP2018516931A JP2017562660A JP2017562660A JP2018516931A JP 2018516931 A JP2018516931 A JP 2018516931A JP 2017562660 A JP2017562660 A JP 2017562660A JP 2017562660 A JP2017562660 A JP 2017562660A JP 2018516931 A JP2018516931 A JP 2018516931A
Authority
JP
Japan
Prior art keywords
binding antibody
seq
functional fragment
binding
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017562660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516931A5 (enExample
Inventor
バッソン，クレイグ
ルッセル，ケリー
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2018516931A publication Critical patent/JP2018516931A/ja
Publication of JP2018516931A5 publication Critical patent/JP2018516931A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2017562660A 2015-06-04 2016-06-02 末梢動脈疾患を処置するためのｉｌ−１ベータ結合抗体の使用 Pending JP2018516931A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562170761P 2015-06-04 2015-06-04
US62/170,761 2015-06-04
PCT/IB2016/053242 WO2016193931A1 (en) 2015-06-04 2016-06-02 Use of il-1 beta binding antibodies to treat peripheral arterial disease

Publications (2)

Publication Number Publication Date
JP2018516931A true JP2018516931A (ja) 2018-06-28
JP2018516931A5 JP2018516931A5 (enExample) 2018-08-16

Family

ID=56132984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017562660A Pending JP2018516931A (ja) 2015-06-04 2016-06-02 末梢動脈疾患を処置するためのｉｌ−１ベータ結合抗体の使用

Country Status (6)

Country Link
US (2) US20210198356A1 (enExample)
EP (1) EP3303388A1 (enExample)
JP (1) JP2018516931A (enExample)
AU (1) AU2016272900A1 (enExample)
CA (1) CA2988055A1 (enExample)
WO (1) WO2016193931A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516850A (ja) * 2018-12-21 2022-03-03 ノバルティス アーゲー 骨髄異形成症候群の治療又は予防におけるＩＬ－１β抗体の使用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2575853A (en) * 2018-07-25 2020-01-29 Robert Wotherspoon Hugh IL-1ß binding antibody
BR112021004999A2 (pt) 2018-09-17 2021-06-08 Yungjin Pharm. Co., Ltd. composto e método de inibição de cdk7 em um sujeito

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US10000565B2 (en) 2012-11-16 2018-06-19 Novartis Ag Use of IL-1 β binding antibodies for treating peripheral arterial disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516850A (ja) * 2018-12-21 2022-03-03 ノバルティス アーゲー 骨髄異形成症候群の治療又は予防におけるＩＬ－１β抗体の使用

Also Published As

Publication number Publication date
WO2016193931A1 (en) 2016-12-08
CA2988055A1 (en) 2016-12-08
EP3303388A1 (en) 2018-04-11
US20230265182A1 (en) 2023-08-24
AU2016272900A1 (en) 2017-12-07
US20210198356A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
EP2919811B1 (en) Use of il-1beta binding antibodies for treating peripheral arterial disease
US12465635B2 (en) Methods of treating inflammatory arthritis using secukinumab
US20250051428A1 (en) Antibodies to amyloid beta
US20210371512A1 (en) Use of IL-1 beta Binding Antibodies
US20230265182A1 (en) Use of il-1 beta binding antibodies to treat peripheral arterial disease
KR20190085963A (ko) 죽상경화성 심혈관 질병을 포함하는, 아테롬성 동맥경화증을 위한 조합 요법
US20180291097A1 (en) Use of il-1 beta binding antibodies to treat peripheral arterial disease
WO2015083120A1 (en) USE OF IL-1β BINDING ANTIBODIES
RU2806304C1 (ru) Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180703